ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · HP_0004322

Short stature

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. Short stature. Diseases, record HP_0004322. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0004322

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
Short stature
Open Targets ID
HP_0004322
Other names
Decreased body height, Height less than 3rd percentile, Small stature, Stature below 3rd percentile
Highest stage of its drugs
Phase 3, for 6 of its 12 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
SOMATROPINCHEMBL1201621ProteinPhase 3ClinicalTrials.gov404039Drugs and targets
SOMAPACITANCHEMBL3707290Small moleculePhase 3ClinicalTrials.gov333Drugs and targets
INPEGSOMATROPINCHEMBL5314747ProteinPhase 3ClinicalTrials.gov111Drugs and targets
LEUPROLIDECHEMBL1201199ProteinPhase 3ClinicalTrials.gov111Drugs and targets
LONAPEGSOMATROPINCHEMBL4298185ProteinPhase 3ClinicalTrials.gov111Drugs and targets
SOMATROGONCHEMBL4297830ProteinPhase 3ClinicalTrials.gov111Drugs and targets
MECASERMINCHEMBL1201716ProteinPhase 2/3ClinicalTrials.gov111Drugs and targets
ETHINYL ESTRADIOLCHEMBL691Small moleculePhase 2ClinicalTrials.gov111Drugs and targets
THEOPHYLLINECHEMBL1355736ProteinPhase 2ClinicalTrials.gov111Drugs and targets
VOSORITIDECHEMBL3707276ProteinPhase 2ClinicalTrials.gov111Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets66

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
GHRGrowth hormone receptor4Growth hormone receptor agonistPhase 3https://conductscience.org/library/genes/2690Drugs and targets
ADORA1Adenosine receptor1Adenosine receptor antagonistPhase 2https://conductscience.org/library/genes/134Drugs and targets
ADORA2AAdenosine receptor1Adenosine receptor antagonistPhase 2https://conductscience.org/library/genes/135Drugs and targets
ADORA2BAdenosine receptor1Adenosine receptor antagonistPhase 2https://conductscience.org/library/genes/136Drugs and targets
ADORA3Adenosine receptor1Adenosine receptor antagonistPhase 2https://conductscience.org/library/genes/140Drugs and targets
COXFA4Mitochondrial complex I (NADH dehydrogenase)1Mitochondrial complex I (NADH dehydrogenase) inhibitorUnknownhttps://conductscience.org/library/genes/4697Drugs and targets
COXFA4L2Mitochondrial complex I (NADH dehydrogenase)1Mitochondrial complex I (NADH dehydrogenase) inhibitorUnknownhttps://conductscience.org/library/genes/56901Drugs and targets
ESR1Estrogen receptor1Estrogen receptor alpha agonistPhase 2https://conductscience.org/library/genes/2099Drugs and targets
GNRHRGonadotropin-releasing hormone receptor1Gonadotropin-releasing hormone receptor agonistPhase 3https://conductscience.org/library/genes/2798Drugs and targets
GPD2Glycerol-3-phosphate dehydrogenase, mitochondrial1Mitochondrial glycerol-3-phosphate dehydrogenase inhibitorUnknownhttps://conductscience.org/library/genes/2820Drugs and targets

1 to 10 of 66

See all 66 targets

Trials43

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT00184717Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)Phase 3982011-07-07Foetal Growth Problem, Small for Gestational AgeSOMATROPINIts record names the diseaseClinicalTrials.gov
NCT00355030Somatropin + Leuprorelin vs Somatropin Alone in Pubertal Children With Idiopathic Short StaturePhase 3912016-10-18Idiopathic Short Stature (ISS)LEUPROLIDE, SOMATROPINIts record names the diseaseClinicalTrials.gov
NCT03878446A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a DayPhase 2622024-06-20Short Stature Children Born Small for Gestational Age (SGA)SOMAPACITAN, SOMATROPINIts record names the diseaseClinicalTrials.gov
NCT01927861Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan SyndromePhase 3512019-10-14Genetic Disorder, Noonan SyndromeSOMATROPINIts record names the diseaseClinicalTrials.gov
NCT05723835A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9Phase 3472025-11-21SGA, Turner Syndrome, Noonan Syndrome, ISSSOMAPACITANIts record names the diseaseClinicalTrials.gov
NCT00125190Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 DeficiencyPhase 2/3452010-04-15Insulin-Like Growth Factor-1 Deficiency, Growth DisordersMECASERMINIts record names the diseaseClinicalTrials.gov
NCT00627523Genotropin Treatment In Very Young Children Born Small For Gestational AgePhase 3432014-09-18Infant, Small for Gestational AgeSOMATROPINIts record names the diseaseClinicalTrials.gov
NCT00174460Somatropin Therapy In Children Born Preterm But Appropriate For Gestational AgePhase 2332009-05-12Growth Hormone Therapy, Infant, Very Low Birth WeightSOMATROPINIts record names the diseaseClinicalTrials.gov
NCT00174187Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid TherapyPhase 3302012-12-04Endocrine System DiseasesSOMATROPINIts record names the diseaseClinicalTrials.gov
NCT00625872Neuromuscular Changes In Small For Gestational Age Children During Somatropin TherapyPhase 3232012-02-29Growth Hormone Therapy, Infant, Small for Gestational AgeSOMATROPINIts record names the diseaseClinicalTrials.gov

1 to 10 of 43

See all 43 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Somatropin and Leuprorelin vs Somatropin: serious adverse events12 of 467 of 4591NCT00355030Trial comparisons
0.033 mg/kg/Day vs 0.066 mg/kg/Day: deaths from any cause0 of 250 of 2651NCT01927861Trial comparisons
0.033 mg/kg/Day vs 0.066 mg/kg/Day: serious adverse events9 of 2510 of 2651NCT01927861Trial comparisons
Genotropin® vs Control: serious adverse events6 of 212 of 2243NCT00627523Trial comparisons
Somatropin vs Control Arm: serious adverse events5 of 181 of 1533NCT00174460Trial comparisons
Somatropin vs Control Arm: serious adverse events0 of 120 of 1123NCT00625872Trial comparisons
Saizen® 0.057 mg/kg/Day vs Saizen® 0.035 mg/kg/Day: Number of Participants With Treatment Emergent Adverse Events (TEAEs)2 of 101 of 1222NCT00249821Trial comparisons
Saizen® 0.057 mg/kg/Day vs Saizen® 0.035 mg/kg/Day: serious adverse events0 of 100 of 1222NCT00249821Trial comparisons

Papers from its trials33

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
32269181RESULT1PubMed
29109363RESULT1PubMed
26363846RESULT1PubMed
24526136RESULT1PubMed
23658497RESULT1PubMed
22788856RESULT1PubMed
22508317RESULT1PubMed
22508151RESULT1PubMed
22156542RESULT1PubMed
41774755DERIVED1PubMed

1 to 10 of 33

See all 33 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0004322

GET https://conductscience.org/api/diseases/v1/HP_0004322/targets?page=2

API referenceFor AI assistants